1.
Blood Cancer J
; 5: e350, 2015 Sep 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26407235
Assuntos
Antineoplásicos/uso terapêutico , Leucemia-Linfoma Linfoblástico de Células T Precursoras/tratamento farmacológico , Tetra-Hidronaftalenos/uso terapêutico , Valina/análogos & derivados , Adolescente , Adulto , Antineoplásicos/farmacocinética , Feminino , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Masculino , Leucemia-Linfoma Linfoblástico de Células T Precursoras/genética , Receptor Notch1/genética , Valina/uso terapêutico , Adulto Jovem
2.
Immunity
; 10(2): 207-17, 1999 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-10072073
RESUMO
Cathepsins have been implicated in the degradation of proteins destined for the MHC class II processing pathway and in the proteolytic removal of invariant chain (Ii), a critical regulator of MHC class II function. Mice lacking the lysosomal cysteine proteinase cathepsin S (catS) demonstrated a profound inhibition of Ii degradation in professional APC in vivo. A marked variation in the generation of MHC class II-bound Ii fragments and presentation of exogenous proteins was observed between B cells, dendritic cells, and macrophages lacking catS. CatS-deficient mice showed diminished susceptibility to collagen-induced arthritis, suggesting a potential therapeutic target for regulation of immune responsiveness.